Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYour first Mounjaro pen has arrived, you've done the injection, and now you're wondering whether what you're feeling is expected. For most people, the symptoms after a Mounjaro injection are gastrointestinal, temporary, and most pronounced in the first day or two after each new dose. The NHS tirzepatide page lists nausea, vomiting, diarrhoea, constipation and indigestion as the most commonly reported effects. These are prescription-only medicines and a GPhC-registered prescriber will have assessed whether tirzepatide is clinically appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture it: Sunday evening, pen done, and by Monday morning your stomach feels unsettled. That's the script for a large share of people starting tirzepatide. Nausea is the most common symptom overall, followed by loose stools or diarrhoea, stomach discomfort, and burping that can feel disproportionate to what you've eaten. Fatigue and a mild headache are also reported by a meaningful number of people, particularly in the first week or two.
The timing matters. Symptoms tend to arrive within a few hours of the injection and resolve within one to three days for most people. They're not random, either. Tirzepatide slows the rate at which food leaves your stomach, so eating a large or fatty meal close to the injection can amplify nausea. Smaller portions, slower eating and staying well hydrated don't eliminate symptoms but they take the edge off for many people.
One quick check worth doing: press gently on the injection site within an hour of administering the pen. A small, slightly raised area is normal. If it's significantly swollen, hot or spreading, that's worth photographing and flagging to your prescriber. Rotating between your abdomen, thigh and upper arm, as described on the injection-site guidance page, helps prevent localised skin reactions from building up.
The NHS medicines page for tirzepatide categorises most of these effects as common (affecting up to 1 in 10 people) to very common (more than 1 in 10). They're not trivial, but they're also not signs that something is going wrong with your treatment.
Once you've settled into your starting dose, the GI effects usually become background noise. Then your prescriber reviews your progress and steps up the dose. That's when symptoms can resurface, often mirroring what you felt at the beginning but typically for a shorter stretch.
This dose-by-dose pattern is why tirzepatide is titrated gradually, beginning at 2.5mg, with each increase handled by your prescriber after they've seen how you're tolerating the current level. The step-up structure isn't bureaucracy; it's designed precisely so your system has time to adjust before the next change. If you want to understand the pen format and dose increments in more detail, our page on Mounjaro injection pens explains how each strength is packaged.
A pattern our prescribers notice fairly often: people feel fine at 5mg, push through to 7.5mg quickly and then feel rough for a fortnight and wonder whether to stop. The answer almost always involves slowing down the titration, not abandoning the medicine. That's a conversation for your clinical team, not a decision to make alone based on how you feel on day three.
Constipation, rather than diarrhoea, tends to become more prominent at higher doses for some people. Fibre intake, fluid intake and movement all help; your prescriber can advise if it becomes a problem worth addressing more directly.
Most of what people experience on Mounjaro is uncomfortable rather than dangerous. There are exceptions, and they're worth knowing clearly.
Severe, persistent stomach pain, particularly pain that radiates towards the back and is accompanied by vomiting, needs urgent medical attention. In January 2026 the MHRA issued a specific Drug Safety Update on GLP-1 medicines, highlighting acute pancreatitis as a known, infrequent but serious risk; the MHRA Yellow Card scheme allows both patients and clinicians to report suspected reactions. Pancreatitis-type pain is distinctly different from ordinary nausea: it doesn't pass in a few hours, it's often severe and central or left-sided in the abdomen, and it may worsen lying flat.
Gallbladder symptoms — right upper abdominal pain, especially after eating fatty food — are also listed in tirzepatide's safety profile. They can be hard to distinguish from ordinary indigestion without clinical assessment, so persistent right-sided pain is worth raising with your prescriber rather than managing with antacids.
Signs of a serious allergic reaction (rash spreading beyond the injection site, facial swelling, difficulty breathing) require emergency help immediately. This is rare, but rapid-onset and unmistakable when it occurs.
Severe diarrhoea or vomiting that prevents you keeping fluids down for more than a day creates a dehydration risk. That, too, warrants a call to your prescriber or 111 rather than waiting it out alone.
For a thorough overview of how tirzepatide works alongside these safety points, the Mounjaro treatment page covers the clinical picture in full. If you have questions about how the Mounjaro injection fits into your treatment plan, or about Mounjaro injections more broadly across the titration schedule, those are both worth reading before your next dose.
Knowing what to expect is useful. Having someone to contact when symptoms feel worse than expected is better. At nume, aftercare is part of the service, available seven days a week, so a rough Tuesday after a new dose doesn't mean waiting until Monday for reassurance.
If you've been considering starting treatment and want to understand more about what the process involves, our weight-loss treatments page outlines how the consultation works. The clinical team, including our lead prescriber whose background you can read about on the clinical team page, reviews every consultation personally before anything is prescribed. If you'd like a step-by-step walkthrough of the process before you begin, our guide on how to use the Mounjaro injection covers technique and timing in plain language. Side-effect management is part of that ongoing clinical relationship, not a one-off transaction.
For people who've been on treatment elsewhere and are moving across, the same aftercare applies. What's available for weight management more broadly, including how different treatments compare, is set out on the weight-loss overview page if that context is helpful.
If you're ready to be assessed, you can start your free consultation today.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.